<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02944461</url>
  </required_header>
  <id_info>
    <org_study_id>ACZ1601</org_study_id>
    <nct_id>NCT02944461</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris</brief_title>
  <official_title>Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Derm Research, PLLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Derm Research, PLLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if Dapsone (Aczone) 7.5% gel is a safe and effective treatment for acne on the
      trunk
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label pilot study to determine the safety and efficacy of Dapsone (Aczone)
      7.5% gel applied daily to the trunk for acne. Subjects will apply Dapsone for 16 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of subjects who achieve at least a two grade improvement and a rating of clear or almost clear on the Investigator Global Assessment (IGA) scale</measure>
    <time_frame>16 weeks</time_frame>
    <description>Investigator will evaluate global acne severity using the IGA scale as follows: 1= Clear Skin, 2 = Almost Clear, 3 = Mild Severity, 4 = Severe, 5 = Very Severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percent reduction in Inflammatory lesion count at Week 16 compared to Baseline</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent reduction in non-inflammatory lesion count at Week 16 compared to baseline</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent reduction in total lesion count at Week 16 compared to Baseline</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Erythema</measure>
    <time_frame>16 weeks</time_frame>
    <description>The Investigator will grade the occurrence of erythema using a scale of : 0 = absent, 1 = Trace, 2 = Mild, 3 = Moderate, 4 = Severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Dryness</measure>
    <time_frame>16 weeks</time_frame>
    <description>The Investigator will grade the occurrence of dryness using a scale of : 0 = absent, 1 = Trace, 2 = Mild, 3 = Moderate, 4 = Severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Peeling</measure>
    <time_frame>16 weeks</time_frame>
    <description>The Investigator will grade the occurrence of peeling using a scale of : 0 = absent, 1 = Trace, 2 = Mild, 3 = Moderate, 4 = Severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Oiliness</measure>
    <time_frame>16 weeks</time_frame>
    <description>The Investigator will grade the occurrence of oiliness using a scale of : 0 = absent, 1 = Trace, 2 = Mild, 3 = Moderate, 4 = Severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Pruritus</measure>
    <time_frame>16 Weeks</time_frame>
    <description>The Investigator will interview the subject to determine the severity of pruritis as per the following: 0 = Absent, 1 = Trace, 2 = Mild, 3 = Moderate, 4 Marked, 5 = Severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Burning</measure>
    <time_frame>16 Weeks</time_frame>
    <description>The Investigator will interview the subject to determine the severity of burning as per the following: 0 = Absent, 1 = Trace, 2 = Mild, 3 = Moderate, 4 Marked, 5 = Severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Subjects will be monitored for signs and symptoms of Adverse Events</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>Dapsone gel 7.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapsone gel 7.5% to be applied to truncal acne once daily for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapsone 7.5 % gel</intervention_name>
    <description>Dapsone gel 7.5% applied once daily to truncal acne</description>
    <arm_group_label>Dapsone gel 7.5%</arm_group_label>
    <other_name>Aczone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects of any race and at least 12 years of age.

          -  Female subjects of childbearing potential must have a negative urine pregnancy test at
             Baseline and practice a reliable method of contraception throughout the study.

          -  Truncal acne IGA score of 3.

          -  Able to understand the requirements of study and sign Informed Consent/HIPAA forms.

        Exclusion Criteria:

          -  Female subjects who are pregnant , breast feeding or are of childbearing potential who
             are not willing to use a reliable method birth control.

          -  Subjects who have an allergy or sensitivity to any component of the test medication.

          -  Subjects who have not complied with the proper wash out periods for prohibited
             medications.

          -  Evidence of recent drug or alcohol abuse.

          -  Skin disease /disorder that might interfere with the diagnosis or evaluation of
             truncal acne.

          -  Exposure to an investigational drug within 30 days of the Baseline visit.

          -  Medical condition that contraindicates the subject's participation in the study.

          -  History of poor cooperation, non-compliance with medical treatment or unreliability.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leon H. Kircik, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>DermResearch PLLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leon H. Kircik, M.D.</last_name>
    <phone>502-451-9000</phone>
    <email>wedoderm@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deborah Zuidema, M.S.N.</last_name>
    <phone>502-456-4161</phone>
    <email>dbzuidema@aol.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dermatology and Laser Surgery</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emil Tanghetti, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>DermResearch, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Zuidema, M.S.N.</last_name>
      <phone>502-456-4161</phone>
      <email>dbzuidema@aol.com</email>
    </contact>
    <investigator>
      <last_name>Leon H. Kircik, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James Q. DelRosso DO, LLC</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Q. DelRosso, D.O.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2016</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapsone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

